In vitro activities of the everninomicin SCH 27899 and other newer antimicrobial agents against Borrelia burgdorferi

被引:15
作者
Dever, LL
Torigian, CV
Barbour, AG
机构
[1] Vet Affairs New Jersey Hlth Care Syst, Med Serv, E Orange, NJ USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA
[3] Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA
[4] Univ Calif Irvine, Coll Med, Dept Med, Irvine, CA 92717 USA
关键词
D O I
10.1128/AAC.43.7.1773
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro activity of the everninomicin antibiotic SCH 27899 against 17 isolates of Borrelia spp. was investigated, MICs ranged from 0.06 to 0.5 mu g/ml. Time-kill studies with the B31 strain of B. burgdorferi demonstrated greater than or equal to 3-log(10)-unit killing after 72 h with concentrations representing four times the MIG. The in vitro activity of four other newer antimicrobial agents, meropenem, cefepime, quinupristin-dalfopristin, and linezolid, was also tested against the B31 strain. Meropenem was the most potent of the latter agents, with an MIC of 0.125 mu g/ml.
引用
收藏
页码:1773 / 1775
页数:3
相关论文
共 15 条
[1]  
ADRIAN PV, 1998, 38 INT C ANT AG CHEM
[2]   ISOLATION OF A CULTIVABLE SPIROCHETE FROM IXODES-RICINUS TICKS OF SWITZERLAND [J].
BARBOUR, AG ;
BURGDORFER, W ;
HAYES, SF ;
PETER, O ;
AESCHLIMANN, A .
CURRENT MICROBIOLOGY, 1983, 8 (02) :123-126
[3]  
BARBOUR AG, 1996, LYME DIS CAUSE CURE
[4]  
BAUERFEIND A, 1997, 37 INT C ANT AG CHEM
[5]   INVITRO ANTIMICROBIAL SUSCEPTIBILITY TESTING OF BORRELIA-BURGDORFERI - A MICRODILUTION MIC METHOD AND TIME-KILL STUDIES [J].
DEVER, LL ;
JORGENSEN, JH ;
BARBOUR, AG .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (10) :2692-2697
[6]  
DEVER LL, ANTIMICROB AGENTS CH, V37, P1115
[7]   In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones [J].
Jones, RN ;
Johnson, DM ;
Erwin, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :720-726
[8]  
JONES RN, 1995, J CLIN MICROBIOL INF, V1, P35
[9]   Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics, and initial clinical experience [J].
Low, DE .
MICROBIAL DRUG RESISTANCE, 1995, 1 (03) :223-234
[10]  
National Committee for Clinical Laboratory Standards, 1993, METH DET BACT ACT AN